Codeine Sulfate

DRUG6 trials

Sponsors

Roxane Laboratories, National Cancer Institute (NCI)

Conditions

Carcinoma In SituCervical Intraepithelial NeoplasiaPainPapillomavirus InfectionsVulvar DiseasesVulvar Neoplasms

Phase 1

Comparative Bioavailability Study of Codeine Sulfate

CompletedNCT01010152

Roxane LaboratoriesPain

Start: 2008-01-31End: 2008-01-31Updated: 2018-01-23

Food Effect Study of Codeine Sulfate

CompletedNCT01009892

Roxane LaboratoriesPain

Start: 2008-01-31End: 2008-01-31Updated: 2018-01-23

Steady State Study of Codeine Sulfate

CompletedNCT01009853

Roxane LaboratoriesPain

Start: 2008-01-31End: 2008-01-31Updated: 2018-01-23

Dose Linearity Study of Codeine Sulfate Under Fasted Conditions

CompletedNCT01009697

Roxane LaboratoriesPain

Start: 2008-03-31End: 2008-04-30Updated: 2018-01-23

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

CompletedNCT02858310

National Cancer Institute (NCI)Carcinoma In Situ, Cervical Intraepithelial Neoplasia, Papillomavirus Infections +2

Start: 2017-01-27End: 2025-07-02Updated: 2026-03-09

Unknown Phase

Pharmacokinetic and Comparative Bioavailability Study of Codeine Sulfate Under Fasted Conditions

CompletedNCT01010139

Roxane LaboratoriesPain

Start: 2006-08-31End: 2006-09-30Updated: 2018-01-23

Related Papers

TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers.

2021-02-08258 citations

Safety and clinical activity of gene-engineered T-cell therapy targeting HPV-16 E7 for epithelial cancers.

Journal of Clinical Oncology2020-05-2020 citations

Engineered t cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.

Journal of Clinical Oncology2018-05-205 citations

Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model

JCI Insight2018-04-18159 citations